Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese allergic asthma drug market is transitioning from traditional treatments to precision medicine, with a focus on monoclonal antibodies targeting various pathways such as IL-5 and IL-4Rα, indicating a shift towards individualized treatment strategies [4][6] - The market size for allergic asthma drugs in China is projected to grow from CNY 11.2 billion in 2018 to CNY 19.6 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%. By 2030, the market is expected to reach CNY 46.7 billion, driven by an expanding patient population and increasing demand for innovative therapies [7][8] - The report highlights the emergence of local companies in the allergic asthma drug market, which are leveraging policy changes and technological advancements to challenge multinational corporations' dominance [17][18] Market Background - The report outlines that allergic asthma is primarily driven by Th2 cell-mediated immune mechanisms and is associated with other allergic conditions [5] - The market is evolving from a focus on inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) to include biologics and targeted therapies, reflecting a significant transformation in treatment approaches [6] Market Status - The Chinese allergic asthma drug market is experiencing robust growth, with over 40 million patients and nearly one million new cases annually, leading to increased drug demand [7][8] - The report notes that the global allergic asthma patient population is expected to rise from 471.3 million in 2018 to 560.6 million by 2030, with China's growth slightly outpacing the global average [11][12] Market Competition - The competitive landscape is characterized by a mix of multinational corporations and local innovators, with companies like GSK and AstraZeneca maintaining significant market shares through established product lines and clinical data [16][17] - Local companies are capitalizing on the "patent cliff" effect and are making strides in the development of biosimilars and targeted therapies, thereby reshaping the competitive dynamics [17][18] Development Trends - The report identifies several key trends, including the acceleration of precision medicine and targeted therapies, the breakthrough of domestic inhalation formulations, and the integration of digital technologies in patient management [33][34][37] - The shift towards a multi-faceted market driven by policy reforms and the coexistence of innovative and cost-effective generic drugs is highlighted as a significant trend [36]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese allergic asthma drug market is transitioning from traditional treatments to precision medicine, with a focus on monoclonal antibodies targeting various pathways such as IL-5 and IL-4Rα, indicating a shift towards individualized treatment strategies [4][6] - The market size for allergic asthma drugs in China is projected to grow from CNY 11.2 billion in 2018 to CNY 19.6 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%. By 2030, the market is expected to reach CNY 46.7 billion, driven by an expanding patient population and increasing demand for innovative therapies [7][8] - The competitive landscape is evolving, with multinational companies like GlaxoSmithKline and AstraZeneca facing challenges from local firms that are leveraging policy changes and technological advancements to capture market share [16][17] Market Background - The report outlines the definition of allergic asthma, emphasizing its association with Th2-mediated immune responses and its links to other allergic conditions [5] - The market is experiencing a profound transformation, moving from traditional inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) to targeted therapies that address specific inflammatory pathways [6] Market Status - The market is characterized by a strong demand for innovative treatments, with over 40 million patients in China and nearly one million new cases annually, leading to a significant increase in drug demand [7][8] - The supply side includes a variety of treatment options, including chemical drugs, allergen immunotherapy (AIT), and biologics, with a focus on improving patient adherence and treatment outcomes [9][10] Market Competition - The competitive assessment includes product innovation capability, market share, and strategic research and development (R&D) positioning as key dimensions for evaluating leading companies in the allergic asthma drug sector [13][14][15] - The report identifies ten recommended brands, highlighting their innovative products and market positions, such as Mabtech's CMAB007 and AstraZeneca's inhalation solutions [21][22][24] Development Trends - The report discusses several key trends shaping the future of the allergic asthma drug market, including the acceleration of precision medicine, advancements in inhalation device technology, and the impact of policy reforms on market dynamics [32][33][34][36][37] - Digitalization and the integration of healthcare services are expected to enhance patient management and treatment adherence, creating a more comprehensive ecosystem for asthma care [37]

Core Viewpoint - Changfeng Pharmaceutical (02652) has received acceptance for its application for the marketing authorization of Budesonide nasal spray from the National Medical Products Administration of the People's Republic of China [1] Product Pipeline - The nasal spray is a complex formulation with high technical barriers, and the company has established a comprehensive product matrix covering various indications and full-course management of respiratory and rhinitis conditions [1] - Existing products in the company's portfolio include: - Fluticasone furoate nasal spray (Shu Fei Min): The first antihistamine-steroid combination nasal spray in China, included in the National Medical Insurance Drug List in 2023 [1] - Mometasone furoate nasal spray: A first-line medication for allergic rhinitis in adults and children aged 3 and above [1] - Budesonide nasal spray (the product in question): Suitable for patients aged 6 and above, targeting seasonal acute episodes, perennial maintenance treatment, and nasal polyps [1] - Olopatadine/Mometasone nasal spray: For moderate to severe allergic rhinitis symptoms in adolescents aged 12 and above and adults [1] Strategic Intent - The acceptance of the Budesonide nasal spray application further enriches the company's product pipeline in the allergic rhinitis field, demonstrating the company's commitment and capability to deepen its layout in the respiratory inhalation treatment sector, providing quality treatment options for patients [1] - The company will actively communicate with the NMPA and advance subsequent review procedures according to regulatory requirements [1]

Core Viewpoint - Changfeng Pharmaceutical's application for the marketing authorization of Budesonide nasal spray has been accepted by the National Medical Products Administration of China, indicating the company's commitment to expanding its product pipeline in the field of allergic rhinitis and respiratory treatments [1] Product Pipeline - The company has established a comprehensive product matrix covering various indications and full-course management of respiratory and rhinitis conditions, leveraging its nasal drug delivery technology platform [1] - Existing products in the company's portfolio include: - Azelastine/Fluticasone nasal spray (Shu Fei Min®): The first antihistamine-steroid combination nasal spray in China, included in the National Medical Insurance Drug List in 2023 [1] - Mometasone nasal spray: A first-line medication for allergic rhinitis in adults and children aged 3 and above [1] - Budesonide nasal spray: Targeted for patients aged 6 and above, addressing seasonal acute episodes, perennial maintenance treatment, and nasal polyps [1] - Olopatadine/Mometasone nasal spray: Designed for adolescents aged 12 and above and adults with moderate to severe allergic rhinitis symptoms [1] Strategic Commitment - The acceptance of the Budesonide nasal spray application further enriches the company's product pipeline in the allergic rhinitis sector, demonstrating its determination and capability to deepen its presence in the respiratory inhalation treatment field [1] - The company will actively communicate with the NMPA and advance subsequent review procedures in accordance with regulatory requirements [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 NMPA受理布地奈德鼻噴霧劑上市許可申請 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 緒言 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司布地奈德鼻噴霧劑（「該 產品」）的上市許可申請（「申請」）已獲中華人民共和國國家藥品監督管理局 （「NMPA」）受理。茲公告相關資訊如下： 1 產品名稱 : 布地奈德鼻噴霧劑 申請類型 : 上市許可申請 受理號 : CYHS2600272/CYHS2600273 申請人 ： 本公司 規格 : 每噴32微克（每瓶120噴）╱每噴64微克（每瓶 120噴） 適應症 ： 治療(1)季節性及常年性過敏性鼻炎；(2)常年性 非過敏性鼻炎；及(3 ...

Core Insights - The recent clinical study of Yuan Da Pharmaceutical's product, Chen Nuo (Eucalyptus Oil Enteric Capsules), has been recognized by an international journal, marking a significant milestone in its evidence-based medical validation [1][3][10] - The study demonstrated the safety and efficacy of Chen Nuo in treating chronic rhinosinusitis over an 8-week period, reinforcing the company's research capabilities in the respiratory field [3][5][7] Product and Market Position - Chen Nuo is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its mucolytic properties and has been included in China's national medical insurance and essential drug lists since 2017 and 2018 respectively [4][10] - The clinical trial involved over 300 patients across 13 hospitals, comparing the efficacy of Chen Nuo combined with Budesonide nasal spray against Budesonide alone [4][5] Clinical Study Results - Results indicated that the combination therapy group showed a statistically significant improvement in symptom control rates compared to the control group, particularly in nasal congestion and discharge by the 8th week [5][7] - The study also highlighted the advantages of the combination therapy for chronic rhinosinusitis patients with a history of smoking, showing greater improvement in CT Lund-Mackay scores [5][7] Future Market Potential - The research supports the inclusion of Chen Nuo in standardized treatment pathways for chronic rhinosinusitis, potentially benefiting over 100 million patients in China, especially those with smoking histories [7] - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7][8] Product Pipeline and Innovation - Yuan Da Pharmaceutical has developed a comprehensive product portfolio in the respiratory and critical care sectors, including treatments for various respiratory diseases and conditions [11][12] - The company is advancing multiple innovative products, including Ryaltris for allergic rhinitis and STC3141 for sepsis, which are expected to enhance its competitive position in the market [12][16] Strategic Development - The company emphasizes innovation and advanced technology in its R&D strategy, aiming to establish a full-cycle management product cluster for chronic respiratory diseases and critical care [16]

Core Viewpoint - The recent clinical study of Yuan Da Pharmaceutical's Cheno® (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in the product's evidence-based medical validation [1][3]. Product and Clinical Research - Cheno® is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its mucolytic properties and has been included in China's national medical insurance and essential drug lists since 2017 and 2018 respectively [4][5]. - The study involved over 300 chronic rhinosinusitis patients across 13 top-tier hospitals in China, comparing the efficacy and safety of Cheno® combined with Budesonide nasal spray against Budesonide alone [4][5]. Study Results - The results indicated that the combination therapy group showed a statistically significant improvement in major symptom scores and symptom control rates compared to the control group [5]. - Notably, the combination therapy was particularly effective for chronic rhinosinusitis patients with a smoking history, demonstrating superior improvement in CT Lund-Mackay scores [5][6]. - The safety profile of Cheno® was confirmed, with no significant difference in adverse event rates compared to the control group [5][6]. Market Position and Future Potential - The study reinforces Cheno®'s clinical value and supports its inclusion in standardized treatment pathways for chronic rhinosinusitis, potentially benefiting over 100 million patients in China, especially those with a smoking history [6]. - Cheno® is not only indicated for chronic rhinosinusitis but also has applications in various respiratory diseases, indicating a vast market potential [6]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from $11.6 billion to $13.8 billion by 2028 at a CAGR of 4.5% [6]. Product Pipeline and Innovation - Yuan Da Pharmaceutical has developed a comprehensive product portfolio in the respiratory and critical care sectors, including innovative formulations for asthma and allergic rhinitis, with several products recently entering the national medical insurance list [11][12]. - The company is also advancing its pipeline with promising candidates for sepsis and other critical conditions, enhancing its competitive edge in the market [12][13]. - The strategic focus on innovation and global expansion aims to solidify the company's position in the respiratory disease management sector [16].

Core Viewpoint - Recent clinical research on Yuan Da Pharmaceutical's product Qino (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in evidence-based medicine for the product [1][3]. Group 1: Clinical Research and Product Validation - The study, led by Professor Wang Dehui from Fudan University, involved over 300 patients across 13 major hospitals in China and demonstrated the safety and efficacy of Qino when used in conjunction with Budesonide nasal spray [4][5]. - Results indicated that the combination therapy significantly improved symptom scores and control rates compared to the control group, particularly in patients with a history of smoking [5][7]. - This research fills a gap in evidence for long-term combination therapy, supporting Qino's inclusion in standardized treatment pathways for chronic rhinosinusitis [7]. Group 2: Market Position and Growth Potential - Qino is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its clinical significance and market leadership in cough and phlegm relief [4][10]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7]. - Yuan Da Pharmaceutical has a diverse product pipeline addressing various respiratory conditions, including asthma and chronic obstructive pulmonary disease, enhancing its competitive edge in the market [11][12]. Group 3: Future Development and Strategic Focus - The company emphasizes innovation and advanced technology in product development, aiming to create a comprehensive management product cluster for chronic respiratory diseases and critical care [16]. - Yuan Da Pharmaceutical's strategic focus on both domestic and international markets is expected to strengthen its industry position and drive valuation growth [15].

Core Viewpoint - The company, YuanDa Pharmaceutical, has demonstrated strong innovation capabilities with significant milestones in nuclear medicine and critical care, indicating a promising growth trajectory and a strategic focus on global expansion [1][3]. Financial Performance - In the first half of the year, YuanDa Pharmaceutical achieved a record revenue of approximately HKD 61.1 billion, with a year-on-year growth of about 13% when excluding the impact of centralized procurement. The net profit for the period was around HKD 11.7 billion [1]. - The revenue from innovative and barrier products accounted for approximately 51% of total revenue, reflecting a year-on-year increase of nearly 15 percentage points [5]. Innovation and Product Development - The company has entered an innovation realization phase, with multiple business segments showing significant product pipeline advancements. The nuclear medicine segment, particularly the Yttrium-90 microsphere injection, saw a revenue increase of nearly 106% year-on-year, reaching approximately HKD 4.2 billion [5][6]. - YuanDa Pharmaceutical is advancing several innovative eye medications and has launched the world's first nasal spray for dry eye syndrome in mainland China, with overseas revenue exceeding USD 100 million, a year-on-year growth of nearly 152% [6]. Clinical Research and Global Expansion - The company is actively conducting clinical research for its innovative product STC3141, which targets sepsis, achieving significant clinical milestones across multiple countries [7]. - YuanDa Pharmaceutical has established a comprehensive global innovation research and development framework, particularly in the nuclear medicine sector, where it is one of only four companies globally to commercialize innovative nuclear drugs [8][12]. Market Response - Following the investor open day on August 20, the company's stock price rose by 4.37%, closing at HKD 9.31, indicating strong market confidence and the potential for a new growth cycle [4]. Strategic Vision - The company aims to become a leader in the global pharmaceutical landscape, emphasizing its commitment to "comprehensive advantages, innovation leadership, and global expansion" [3][13].

Core Viewpoint - The company, Yuan Da Pharmaceutical, has demonstrated strong innovation capabilities with significant milestones in nuclear medicine and critical care, indicating a promising growth trajectory and a strategic focus on global expansion [1][3]. Financial Performance - In the first half of the year, Yuan Da Pharmaceutical achieved a record revenue of approximately HKD 61.1 billion, with a year-on-year growth of about 13% when excluding the impact of centralized procurement. The net profit for the period was around HKD 11.7 billion [1][4]. Innovation and Product Development - The company has entered an innovation realization phase, with innovative and barrier products accounting for approximately 51% of revenue, a year-on-year increase of nearly 15 percentage points. The nuclear medicine segment, particularly the Yttrium-90 microsphere injection, saw a remarkable revenue growth of nearly 106% year-on-year, reaching about HKD 4.2 billion [4][5]. - Yuan Da Pharmaceutical has a robust pipeline with 133 projects under research, including 42 innovative projects, which are expected to drive long-term growth [5][6]. Global Expansion Strategy - The company aims to become a leader in the global layout of Chinese pharmaceutical enterprises, actively participating in global competition and promoting "Chinese manufacturing" on the international stage [3][12]. - Yuan Da Pharmaceutical has established a comprehensive global innovation research and development foundation, particularly in the nuclear medicine sector, where it is one of only four companies globally to commercialize innovative nuclear medicines [7][11]. Clinical Research and Milestones - The company’s self-developed product STC3141 for sepsis has successfully reached the domestic Phase II clinical research endpoint, potentially addressing a significant global health challenge [6][10]. - Multiple projects have received clinical trial qualifications in regions including the United States, Australia, and Europe, indicating a well-established global value realization pathway for innovative drugs [10][11]. Market Response - Following the investor open day, the company's stock price increased by 4.37%, closing at HKD 9.31, suggesting a potential new growth cycle for the company's shares [4].